References
- Uusitupa MI, Niskanen LK, Siitonen O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27–36.
- Jarrett RJ. Risk factors for coronary heart disease in diabetes mellitus. Diabetes. 1992;41(Suppl 2):1–3.
- Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421–1430.
- Simons LA, McCallum J, Friedlander Y, et al. Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. Aust N Z J Med. 1996;26:66–74.
- Niskanen L, Turpeinen A, Penttilä I, et al. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998;21:1861–1869.
- Östgren CJ, Lindblad U, Melander A, et al. Survival in patients with type 2 diabetes in a Swedish community: skaraborg hypertension and diabetes project. Diabetes Care. 2002;25:1297–1302.
- Solfrizzi V, Panza F, Colacicco AM, et al. Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or =65 years of age (the Italian longitudinal study on aging). Am J Cardiol. 2002;89:825–829.
- Roselli Della Rovere G, Lapolla A, Sartore G, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46–51.
- Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals wal.ith and without diabetes. Diabetes Care. 2005;28:1916–1921.
- Zoppini G, Targher G, Negri C, et al. Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction. Atherosclerosis. 2010;212:287–291.
- Hero C, Svensson AM, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabet Med. 2016;33:316–323.
- Sharif S, van der Graaf Y, Nathoe HM, et al. HDL cholesterol as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424–1430.
- Feng Q, Wei WQ, Chung CP, et al. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med. 2018;15:e1002642.
- de Lorgeril M, Hamazaki T, Kostucki W, et al. Is the use of cholesterol-lowering drugs for the prevention of cardiovascular complications in type 2 diabetics evidence-based? A systematic review. Rev Recent Clin Trials. 2012;7:150–157.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
- Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109–1117.
- Cai R, Yuan Y, Zhou Y, et al. Lower intensified target LDL-C level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. PLoS One. 2014;9:e104922. eCollection 2014.